Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield NM CVD Risk Coverage Update…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - New MexicoPolicy RPLAB020

    Cardiovascular Disease Risk Assessment

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB020 alerts

    Get alerted when Policy RPLAB020 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSNM reimbursement policy for laboratory tests used in cardiovascular disease (CVD) risk assessment and screening, including which lipid and biomarker tests are reimbursable or not, and applicable testing intervals for various clinical scenarios.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyCardiovascular Disease Risk Assessment
    Policy CodePolicy RPLAB020
    Change TypeMaterial updates to screening intervals, hs-CRP reimbursement limits, and Lp(a) coverage
    Effective DateSep 4, 2026
    Last ReviewSep 4, 2026
    Next Review Date
    Key ActionSubmit claims with accurate documentation and valid code combinations; claims may be reviewed and require additional documentation.
    SourceLink
    POLICY UPDATE CHANGES

    Changed routine screening interval from every 4 years to every 5 years for a specified population.

    Removed allowance for hs-CRP as a general reimbursable test for CVD risk assessment; limited or conditional reimbursement applied.

    Measurement of lipoprotein(a) (Lp(a)) once per lifetime (age ≥18) is considered reimbursable.

    Added reimbursement code 83876 and later code 0541U and others across updates.

    Annual lipid panel screening permitted for individuals at increased risk of dyslipidemia.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Every 5 yearsrecommended lipid panel screening interval for ages 18-79
    OnceLp(a) measurement reimbursable frequency (≥18 years)
    Not reimbursableCRP, hs-CRP, hs-cTnT, homocysteine
    4–12 wkslipid testing after statin initiation/change
    Annuallipid panel for increased CVD risk
    ~111references cited

    Coverage Criteria for CVD Risk Laboratory Testing

    Reimbursable and non-reimbursable CVD risk tests and intervals

    Specifies which tests and testing intervals are reimbursable for cardiovascular disease (CVD) risk assessment and which tests are excluded.

    ALL of the following

    • General population

      • Every 5 years for individuals ages 18–79 years (routine screening).
    • Increased CVD risk

      • Annually for individuals at increased risk for cardiovascular disease as defined by the 2013 ACC/AHA Pooled Cohort Equations (PCEs) to calculate 10-year risk (note: 10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger).
      • Annually for individuals at increased risk of dyslipidemia due to conditions including: obesity/metabolic syndrome; nephrotic syndrome; hypothyroidism; hyperthyroidism; pancreatitis; diabetes; chronic kidney disease; Cushing syndrome; pregnancy; cholestatic liver disease; adult lipid metabolism disorders (e.g., Gaucher disease); being on long-term drug therapy that requires lipid monitoring (e.g., isotretinoin, antipsychotics); family history of elevated lipids; premature heart disease; history of stroke.

    ALL of the following

    • Obtain baseline lipid levels before initiating statin therapy.
    • Repeat testing every 4 to 12 weeks after initiation or change of therapy.
    • Subsequent monitoring every 3 to 12 months as clinically indicated.

    ALL of the following

    • Obtain baseline lipid levels before initiating ART.
    • Repeat testing every 1 to 3 months after initiation or change of therapy.
    • If stable with no medication changes, repeat testing every 6 to 12 months.

    ALL of the following

    • Measurement of apoB may be reimbursable for selected indications including hypertriglyceridemia, diabetes, obesity/metabolic syndrome, other dyslipidemias (e.g., very low LDL-C), individuals on lipid therapy, or those suspected of familial Dysbetalipoproteinemia or familial combined hyperlipidemia.
    • Frequency limit: no more than once every four weeks.

    ALL of the following

    • Measurement of Lp(a) may be reimbursable once per lifetime when performed at age 18 years or older.

    ALL of the following

    • Conventional CRP testing is not reimbursable for CVD risk assessment.
    • High-sensitivity CRP (hs-CRP) is not reimbursable for general CVD risk assessment.

    ALL of the following

    • High-sensitivity cardiac troponin (hs-cTnT) is not reimbursable for CVD risk assessment in the outpatient setting.
    • Homocysteine testing is not reimbursable for CVD risk assessment.
    • Novel lipid and non-lipid biomarkers (e.g., apoAI, apoE, B-type natriuretic peptide, cystatin C, fibrinogen, leptin, LDL/HDL subclasses, myeloperoxidase) are not reimbursable for CVD risk assessment.
    • CVD risk panels consisting of multiple individual biomarkers (other than a simple lipid panel) are not reimbursable.
    • Lipoprotein-associated phospholipase A2 (Lp-PLA2) and secretory type II phospholipase A2 (SPLA2-IIA) are not reimbursable.
    • Serum intermediate density lipoproteins, long-chain omega-3 fatty acids in red blood cell membranes, and all other tests for assessing CVD risk not explicitly allowed are not reimbursable.

    ALL of the following

    • A simple lipid panel is generally composed of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides; calculated ratios may be reported. Other tests (e.g., apolipoproteins, particle number/size, Lp(a)) are not components of a simple lipid panel.
    • Procedure codes listed in policy are examples; inclusion of a code does not guarantee coverage. Providers must follow Plan documents and contracts governing coverage and submission requirements.

    ALL of the following

    • Not all requirements apply to every product; providers should review specific Plan documents for eligible coverage.
    • If there is a conflict between this reimbursement policy and a Plan document or provider contract, the Plan document or contract governs, and BCBSNM may use discretion in interpretation.

    Reference evidence nodes

    References and guideline sources informing coverage determinations include systematic reviews, meta-analyses, guideline statements, and public health resources.

    ALL of the following

    • Systematic reviews, meta-analyses, and primary studies addressing biomarkers and their associations with cardiovascular disease (examples cited in references numbered ~37–127).
    • Evidence from Mendelian randomization and large observational cohorts informing biomarker causality and association with CVD outcomes.

    ALL of the following

    • Key guideline citations include: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease; 2013 and 2018 ACC/AHA cholesterol guidelines; ESC/EAS dyslipidemia guidelines (2021/2025 updates referenced); and ADA Standards of Care.
    • Guidelines were used to inform screening intervals, definitions of increased risk, and selective use of biomarkers (e.g., Lp(a), apoB).

    Reimbursement criteria for CVD risk laboratory testing

    Coverage and frequency rules as stated in policy history and reimbursement information updates.

    ALL of the following

    • Routine lipid screening interval was updated from every 4 years to every 5 years for individuals ages 18–79 (policy history revision).
    • Lipid panel screening reimbursable annually for individuals with increased risk of dyslipidemia; this annual recommendation was added/clarified in policy history.

    ALL of the following

    • Policy revised to allow measurement of Lp(a) once per lifetime when performed at age ≥18 years.

    ALL of the following

    • General reimbursement for hs-CRP was removed; however, for individuals for whom a risk-based treatment decision is uncertain after quantitative risk assessment, hs-CRP testing may be reimbursable with these limits: one initial test for screening; if initial screen is abnormal, confirmatory testing no sooner than two weeks after the initial test; annual screening thereafter for those with confirmed elevated hs-CRP.

    Procedure and Billing Codes

    Example procedure codes referencedCPT
    80061Lipid panel
    83695Lipoprotein(a) assay
    82172Apolipoprotein assay
    86140C-reactive protein
    86141C-reactive protein, high sensitivity
    84484Troponin, quantitative
    83090Homocysteine assay
    83698Lipoprotein-associated phospholipase A2 (Lp-PLA2)
    83876Myeloperoxidase assay
    No procedure or diagnosis codes provided in this references sectionmixed
    Policy-referenced test codesmixed
    83876Added to policy (unspecified test mapping in history)
    0541UAdded to policy per 04/15/2025 update
    0415UAdded 03/01/2024
    0019MAdded 03/01/2024
    84512Added in a prior update
    apoB frequency limit
    Frequency limitMeasurement of apolipoprotein B (apoB) reimbursable no more than once every four weeks.
    Indications (examples)Hypertriglyceridemia; diabetes mellitus; obesity or metabolic syndrome; other dyslipidemias (e.g., very low LDL-C); individuals on lipid therapy; suspected familial dysbetalipoproteinemia or familial combined hyperlipidemia.
    Relevant policy noteProcedure code inclusion does not guarantee coverage; reimbursement depends on clinical indication and Plan documentation.
    Policy-referenced procedure codes and coding notes
    CPT/HCPCS examples included in policy80061 (Lipid panel); 83695 (Lipoprotein[a] assay); 82172 (Apolipoprotein assay); 86140 (C-reactive protein); 86141 (C-reactive protein, high sensitivity); 84484 (Troponin, quantitative); 83090 (Homocysteine); 83698 (Lp-PLA2); 83876 (Myeloperoxidase).

    Provider Actions, Documentation & Billing Guidance

    Documentation Required

    Documentation and claims submission — submit accurate coded claims and retain supporting records

    Providers must submit accurate documentation of services rendered and use valid code combinations from HIPAA‑approved code sets; claims are subject to code edits, review, and may require additional documentation upon request. Code selection should follow industry coding guidance (e.g., CPT, HCPCS, ICD‑10‑CM, CMS NCCI) and providers should be prepared to supply supporting records if the claim is audited.

    • Submit claims using valid HIPAA‑approved code sets and appropriate code combinations per industry standards (CPT, HCPCS, ICD‑10‑CM, Uniform Billing rules).
    • Claims are subject to code edit protocols, plan and contract terms, and may require submission of additional documentation upon request.
    • Provider contract or Plan documents govern in case of conflict with this reimbursement policy.
    Note

    Guideline references provided for clinical decision‑making (informational)

    This policy cites major clinical practice guidelines and consensus statements (e.g., ACC/AHA primary prevention and cholesterol guidelines) and other society guidance as informational resources to guide clinical decision‑making; these citations do not constitute prior authorization requirements.

    Definitions and Key Terms

    Simple lipid panel
    Core componentsTotal cholesterol; LDL cholesterol; HDL cholesterol; Triglycerides
    Additional reported valuesCertain calculated ratios (e.g., total/HDL cholesterol) may be reported
    ExclusionsApolipoproteins, particle number/size, Lp(a) and other specialized tests are not components of a simple lipid panel
    Increased CVD risk (for testing frequency)
    Included populationsIndividuals identified by Pooled Cohort Equations 10-year risk and those with conditions such as diabetes, obesity/metabolic syndrome, nephrotic syndrome, thyroid disease, pancreatitis, chronic kidney disease, pregnancy, lipid metabolism disorders, long-term lipid-impacting drug therapy, family history of elevated lipids, premature heart disease, and history of stroke
    Screening frequency
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyCardiovascular Disease Risk Assessment
    Policy CodePolicy RPLAB020
    Change TypeMaterial updates to screening intervals, hs-CRP reimbursement limits, and Lp(a) coverage
    Effective DateSep 4, 2026
    Last ReviewSep 4, 2026
    Next Review Date
    Key ActionSubmit claims with accurate documentation and valid code combinations; claims may be reviewed and require additional documentation.
    SourceLink
    On This Page
    Coverage Criteria for CVD Risk Laboratory TestingProcedure and Billing CodesProvider Actions, Documentation & Billing GuidanceDefinitions and Key Terms

    ALL of the following

    • CDC cardiovascular biomarker standardization and Lipids Standardization Program documents are cited for laboratory standardization considerations.
    • CMS lipid testing national coverage documentation is referenced for coverage context.

    ALL of the following

    • References address apolipoprotein B clinical management, Lp(a) scientific statements, associations of inflammatory markers (e.g., fibrinogen, CRP), troponin, and other biomarkers with CVD risk.
    • Evidence on lipid-lowering therapies, statin benefits, and the implications for testing frequency and monitoring are included among cited sources.

    ALL of the following

    • References include peer-reviewed journals, society guideline documents, and public health agency resources (CDC, CMS) used to support policy positions on reimbursable tests and testing intervals.
  1. Conventional (non–high-sensitivity) CRP testing remains not reimbursable for CVD risk assessment.
  2. ALL of the following

    • Policy history specifies that Lp-PLA2 is not reimbursable for any indication; additional tests (e.g., myeloperoxidase) are listed as not reimbursable in updates.
    • Policy history documents addition of billing/coding updates across revisions, including codes such as 83876, 0541U, 0415U, 0019M, and 84512 to align reimbursement for specific tests.

    ALL of the following

    • Policy history entries document that changes were made based on guideline updates (e.g., NLA, VA/DoD, USPSTF) and literature reviews; providers should consult current policy history for effective dates of these changes.
    Coding additions in historyPolicy history documents addition of codes 83876, 0541U, 0415U, 0019M, and 84512 in updates to support covered tests.
    Coding caveatListing a procedure code is illustrative and does not alone confer coverage; clinical indication and Plan documents govern reimbursement.
    hs-CRP confirmatory interval
    Confirmatory interval for hs-CRPIf initial hs-CRP is abnormal, a confirmatory hs-CRP test may be reimbursable no sooner than two weeks after the initial test.
    Initial and follow-up sequenceFor individuals with uncertain risk-based treatment decisions: one initial hs-CRP test; confirmatory test ≥2 weeks after an abnormal initial result; annual screening if elevated hs-CRP is confirmed.
    General non-reimbursementHs-CRP testing is not reimbursable for general CVD risk assessment outside the limited scenario described above; conventional CRP is not reimbursable for CVD risk assessment.
    • Key cited guidelines include the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease and ACC/AHA cholesterol guidance (2013, 2018).
    • The references list includes multiple professional society and consensus statements used to inform coverage determinations.
    Note

    Public health and coverage‑related references (CDC, CMS) — informational

    Public health and coverage resources (CDC biomarker/lipid standardization programs and CMS lipid testing guidance) are cited as supporting evidence; the references section does not establish a separate prior authorization process or explicit billing actions.

    • CDC resources cited include the Cardiovascular Disease Biomarker Standardization Programs and Lipids Standardization Program documents.
    • CMS lipid testing NCD is referenced; policy history documents reflect coding and reimbursement updates but do not create a prior authorization requirement.
    Billing Rule

    Billing code updates and conditional reimbursement — code additions and applicable conditions

    Policy history documents additions and revisions of CPT/HCPCS and other billing codes to align reimbursement for CVD risk laboratory tests and specify conditional reimbursement rules (e.g., for hs‑CRP and one‑time Lp(a)).

    • Policy history shows addition of codes such as 83876, 0541U, 0415U, 0019M, and 84512 across updates to support covered tests.
    • Conditional reimbursement is specified for hs‑CRP (limited to uncertain risk‑based treatment decisions with initial, confirmatory ≥2 weeks, and annual if confirmed) and Lp(a) (one lifetime measurement ≥18 years).
    Annual lipid panel reimbursement for individuals at increased risk
    Risk calculation note10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger
    ACC/AHA guidelines
    RoleACC/AHA guideline references used to inform prevention and treatment recommendations for cardiovascular risk and lipid management
    Examples cited2019 ACC/AHA Primary Prevention guideline; 2013/2018 ACC/AHA cholesterol guidance
    Use in policyGuidelines inform risk assessment tools (e.g., PCE) and risk-enhancing factor considerations
    CDC/CMS resources
    RoleCDC and CMS resources cited for public health standardization and coverage guidance
    Examples citedCDC Cardiovascular Disease Biomarker Standardization Programs; CDC Lipids Standardization Program; CMS Lipid Testing NCD
    PurposeSupport laboratory standardization and policy coverage references
    high-sensitivity C-reactive protein testing
    Coverage stancehs-CRP is not reimbursable for general CVD risk assessment but may be reimbursable in select cases where risk-based treatment decisions remain uncertain
    Allowed frequencies (conditional)One initial test; confirmatory testing no sooner than two weeks after an abnormal initial result; annual screening if confirmed elevated
    Conventional CRPConventional (non-high-sensitivity) CRP testing is not reimbursable for CVD risk assessment
    lipoprotein(a) measurement
    Allowed frequencyOne-time measurement once per lifetime for individuals aged ≥18 years
    PurposeMeasurement considered for lifetime risk assessment of Lp(a) as a genetically determined CVD risk factor
    Policy noteRevised in policy history to explicitly allow Lp(a) measurement once during adulthood